Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 716 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99 - NCT07092514RecruitingPhase 2
Comparing two doses of lenvatinib for thyroid cancer not helped by iodine
This study compares two doses of lenvatinib (24 mg vs 10 mg per day) to see which works better for people with thyroid cancer that no longer responds to radioactive iodine. It's for those whose cancer is growing or causing symptoms.
St Louis, MissouriAges 18 years+ - NCT07089641RecruitingPhase 1
Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06972628RecruitingPhase 2
177Lu-PSMA-617 for advanced prostate cancer with bone spread
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Houston, TexasAges 18 years+ - NCT06866041Recruiting
Prostate cancer markers and imaging for low-risk patients on active surveillance
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Milan, ItalyAges 45–80 - NCT06863194RecruitingPhase 1/Phase 2
Probiotics and kidney disease progression trial
This trial tests whether taking a probiotic supplement can slow down the decline of kidney function in people with moderate chronic kidney disease (CKD stages 3 and 4). If you have stable kidney disease and are not already taking probiotics, joining this study could help researchers find a new way to protect your kidneys.
Al Mansurah, DakahliyaAges 18 years+ - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT07070791Recruiting
Exercise program for arm strength and fitness after breast cancer
This trial tests whether a combination of arm-strengthening and aerobic exercises helps breast cancer patients who are at least 15 months past surgery and not very active. The goal is to see if this home-based program improves arm function and overall fitness.
Ankara, StateAges 18–80 - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT07061626RecruitingPhase 1
Radioactive drug for recurrent ependymoma and high-grade glioma
This trial tests a radioactive drug (Rhenium-186) injected directly into the brain tumor to see the highest safe dose for children and young adults with ependymoma or high-grade glioma that has come back or is not responding to standard treatments. It may help shrink the tumor without needing surgery right away.
Chicago, IllinoisAges 6–21 - NCT07063875RecruitingPhase 1/Phase 2
Adding IL-2 to tebentafusp for advanced eye cancer
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
Sydney, New South WalesAges 18 years+ - NCT07048106Recruiting
Study on eye changes in people with PXE
This study uses special eye imaging to track changes caused by PXE, a rare genetic condition. It may help researchers understand how PXE affects the eyes over time.
Bonn, North Rhine-WestphaliaAges Any age - NCT07038967Recruiting
Cataract surgery and diabetic macular edema progression
This trial studies how diabetic macular edema (swelling in the center of the retina) might change after cataract surgery. It may help doctors understand if surgery is safe for people with this condition.
CairoAges 18 years+ - NCT07043972RecruitingPhase 2
Gemcitabine and carboplatin after EV-pembrolizumab for bladder cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07036341Recruiting
Recovering after a hip fracture: protein and exercise
This study tests whether extra protein in your diet combined with exercise can help you recover better after a hip fracture, improving your bone and muscle health and quality of life.
ArnhemAges 65 years+ - NCT07028827RecruitingPhase 3
Atropine eye drops for nearsightedness in kids and teens
This trial tests whether atropine eye drops can slow down worsening nearsightedness (myopia) in children and teenagers. It may help keep their eyesight from getting worse over time.
TiranaAges 3–17 - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT07024251Recruiting
Collecting biological samples for oral and maxillofacial research
This study collects leftover samples (like tissue, saliva, or blood) from routine dental visits or oral surgeries. The samples are used to learn more about mouth and jaw diseases, with no extra procedures needed.
Milan, ItalyAges 18 years+ - NCT06995170Recruiting
Polyamines and IBD progression study
This study looks at how certain natural chemicals called polyamines relate to the activity of inflammatory bowel disease (IBD). It aims to understand if these chemicals can help predict disease progression.
Xi'an, ShaanxiAges 18–65 - NCT06722534Recruiting
Celecoxib to prevent polyps from growing in Peutz-Jeghers Syndrome
This trial is testing if the medication celecoxib can stop or slow the growth of polyps in people with Peutz-Jeghers Syndrome (PJS). It may help reduce the need for surgery and lower the risk of complications.
Xi'an, ShaanxiAges 8 years+ - NCT07021560Recruiting
ZEISS MyoCare glasses for slowing myopia in children
This trial tests whether ZEISS MyoCare glasses can slow down the worsening of nearsightedness (myopia) in children. It is designed for kids aged 7 to 13 who are already nearsighted and need stronger glasses over time.
HanoiAges 7–13 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT07014111Recruiting
Fight Fatigue: muscle relaxation and walking for dialysis patients
This study tests a simple program that combines muscle relaxation exercises and walking to help reduce fatigue in people with end-stage kidney disease who are on dialysis. You'll receive text messages to guide you and track your progress.
Chicago, IllinoisAges 18 years+ - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 716 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.